Eikon Therapeutics priced an upsized IPO that will raise roughly $381 million to advance its cancer drug candidates, while Agomab Therapeutics and SpyGlass Pharma together raised about $350 million in separate Nasdaq listings. These offerings follow a string of biotech IPOs this week and mark a pickup in public financing after a multi‑year slowdown. Companies leveraged investor appetite for oncology, immunology, and specialty therapeutics to secure capital for clinical programs and platform scale‑up. The strong proceeds—but mixed aftermarket performance in some cases—underscore renewed but cautious investor interest: public markets are validating select late‑stage and platform plays, while pricing and day‑one stock moves will influence future windows for providers and founders.